
FDA approval of linerixibat brings the first targeted oral relief for cholestatic pruritus in primary biliary cholangitis, easing relentless autoimmune itch fast.

FDA approval of linerixibat brings the first targeted oral relief for cholestatic pruritus in primary biliary cholangitis, easing relentless autoimmune itch fast.

Icotrokinra, a first-in-class oral IL-23 receptor blocker, fills a long-standing gap in the treatment of moderate to severe plaque psoriasis.

Sharon Nachman, MD, division chief for pediatric infectious disease at Stony Brook Children's Hospital, shares her reaction to the court ruling blocking the scaled-back childhood vaccine schedule.

Interoperability gaps in EHRs hinder pharmacists' ability to ensure safe medication practices, impacting patient safety and care transitions.

Dual-target flu immunity to HA and NA halves airborne spread in ferrets without escape mutations, reshaping next-generation vaccines and pharmacist counseling.

New American College of Cardiology/American Heart Association dyslipidemia guidelines reset LDL goals, add PREVENT risk scoring, and expand Lp(a)/apoB testing for earlier, tougher prevention.

Acquiring advanced certifications equips pharmacy technicians with a clear pathway to increased salary potential and long-term financial stability.

Real-world data show racial gaps in multiple myeloma CAR T-cell therapy; pharmacists in oncology can boost referrals, equity, and access.

RUNX1 in microglia helps predict opioid pain relief, higher morphine needs, and withdrawal severity—pointing to genetic screening and safer, personalized pain management.

Daily walking and resistance bands during chemotherapy help curb chemo brain and brain fog, keeping patients active and sharper at home.

Finerenone slows nondiabetic chronic kidney disease, improving eGFR slope and signaling a possible FDA expansion.

Analysis reveals critical price volatility patterns affecting pharmacy inventory management.

The VIVID trial finds high-dose vitamin D3 doesn’t cut COVID care visits but hints at fewer long COVID symptoms.

Explore how pharmacists elevate electrophysiology care and get a preview of ACC 2026 trials on AF, HFpEF, pulmonary embolism, and hypertension.

Improved risk stratification for coadministration of linezolid with serotonergic agents has the potential to optimize its indications in clinical practice.

Despite persistent gaps in cardiovascular risk management, pharmacists are proving essential in improving LDL control, guiding statin use, and supporting evidence-based care across clinical settings.

FDA expands Arexvy RSV vaccine to at-risk adults 18-49, backed by phase 3b data—what it means for patients and pharmacists.

Although the rates of gabapentin use without a prescription were nearly double those of prescribed use, the trends are decreasing over time.

An Intermountain Health study finds atrial fibrillation present in 25% of patients with peripheral arterial disease, with major cardiovascular events occurring in 46% within 3 years.

Pharmacists have become central to titration, access, patient education, and logistics as GLP-1 use grows and cardiometabolic management evolves.

Ashlan J. Kunz Coyne drives innovative research to combat multidrug-resistant infections and enhance patient care.

Rapid RSV testing in pediatrics cuts unnecessary antibiotic use in young children with viral lung infections.


Peer Reviewed
Although the overall proportion of female authors in pharmacy publishing exceeds the representation of women in the pharmacy, medical, and pharmaceutical science workforces, women are more likely to be first authors than senior authors.

Ruxolitinib can shape myelofibrosis care, and other drugs' dosing, resistance, and next-generation combinations are under study.

Stable HCV E1E2 proteins on self-assembling nanoparticles spark strong mouse antibodies, advancing a long-sought hepatitis C vaccine.

Data from a phase 2 response-adapted trial identify CD38 expression, plasma cell phenotype, and immune microenvironment as critical determinants of single-agent daratumumab efficacy.

Peer Reviewed
This case report highlights pharmacists’ collaborative role in optimizing care transitions and diabetes management for a patient newly diagnosed with latent autoimmune diabetes in adults.

Pharmacists are trusted experts in medication management and clinical care who bring essential clinical expertise to PBM reform efforts.

Sibeprenlimab, a new APRIL blocker, cuts proteinuria in IgA nephropathy.